The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patientsMyeloma, News25 July 2025
EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myelomaAccess, Myeloma27 June 2025
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, Myeloma28 May 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, Myeloma29 April 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, News3 March 2025
